Evaluation of Predictors of Ineffectiveness of Antiviral Therapy for Chronic Hepatitis C in the Republic of Kazakhstan

Arailym Maikenova, Alexander Nersesov, Elmira Kuantay, Mukhtar Kulimbet, Yerkezhan Yerlanova, Massimo Giuseppe Colombo, Chavdar Pavlov, Almagul Jumabayeva, Balzhan Nugmanova, Venera Ayupova, Raissa Yarunina, Assel Kaulybekova, Ulzhalgas Alimkhan, Nazugum Churukova, Ilyas Kaltayev, Gulnar Alpysbayeva, Roza Atasheva, Aliya Balabek, Tatyana Kassymova, Meirambek Kurmangazin, Askar Kyzdarbekov, Gulnara Mukanova, Aiman Nurpeisova, Nazigul Sapargaliyeva, Kunsulu Shamsivaliyeva, Saule Zhumatayeva, Yuliya Ligay
2023 · doi:10.21203/rs.3.rs-3725698/v1
preprint OA: closed CC-BY-4.0
📄 Open PDF View at publisher

Abstract

This study aims to identify the predictors of ineffectiveness in antiviral therapy for chronic hepatitis C (CHC) in Kazakhstan. The rising prevalence and mortality rates associated with CHC globally and within Kazakhstan underscore the need for effective antiviral treatment strategies. Despite the introduction of direct-acting antiviral agents (DAAs) with high cure rates, a subset of patients fails to achieve a sustained virological response (SVR). We conducted a multicenter retrospective matched case-control study across 13 regions of Kazakhstan, including 812 patients with CHC. The study involved patients registered in healthcare organizations who had received DAAs, focusing on those who did not reach SVR. Variables such as demographic characteristics, virological status, stage of liver disease, comorbidities, lifestyle factors, therapy regimen, and patient adherence were analyzed. Logistic regression analysis identified multiple factors associated with increased risk of non-response to therapy, including comorbid conditions like arterial hypertension, hepatocellular carcinoma, and lifestyle factors. The study highlights the complexity of CHC treatment in Kazakhstan, emphasizing the need for personalized treatment plans and addressing comorbid conditions and lifestyle factors. This research contributes to understanding the multifaceted nature of CHC treatment response and aids in optimizing therapeutic strategies in similar healthcare settings.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (18)

Source provenance

crossref
last seen: 2026-06-13T17:26:44.665483+00:00
europepmc
last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall
last seen: 2026-05-22T02:00:06.705733+00:00
License: CC-BY-4.0